{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'be any unfavourable and unintended sign (including an abnormal laboratory finding)', 'symptom or disease (new or exacerbated) temporally associated with the use of a', 'Medicinal Product. For a marketed Medicinal Product, this can also include failure', 'to produce expected benefits (i.e. lack of efficacy, with or without an adverse event),', 'In order for GSK to comply this Canadian regulatory requirement, Canadian investigators', 'are required to collect, record and report lack of efficacy events as per the table in', 'Appendix 4 Section 12.4.1\".', \"All paper forms are required to be faxed to GSK Canada's Drug Safety department at\", 'PP', 'within 24 hrs of first awareness.', 'Appendix 4, Section 12.4.1', 'Rationale for change: To add a small table about reporting of AEs.', 'Revised text. The table below was added.', 'Adverse', 'Electronic case record', 'Paper form only', 'Electronic case', 'Event', 'form (eCRF) only', 'record form', 'criteria', '(eCRF) + Paper', 'form', 'Non serious', 'Non drug related lack of', 'Drug related lack of', 'Drug related lack', 'efficacy reports with', 'efficacy reports', 'of efficacy with', 'associated signs or', 'without associated', 'associated signs or', 'symptoms or clinical', 'signs or symptoms or', 'symptoms or', 'sequelae', 'clinical sequelae.', 'clinical sequelae', 'Serious', 'Non drug related lack of', 'Drug related lack of', 'Drug related lack', 'efficacy reports with', 'efficacy reports', 'of efficacy reports', 'associated signs or', 'without associated', 'with associated', 'symptoms or clinical', 'signs or symptoms or', 'signs or symptoms', 'sequelae', 'clinical sequelae.', 'or clinical sequelae', 'Appendix 4, Section 12.4.4, second bullet point', 'Revised text:', 'The investigator will then record all relevant information regarding an AE/SAE in the', 'electronic CRF \"and/or paper form as applicable\". Added', 'Section 12.4.6, second bullet point', 'Revised text:', '\"For lack of efficacy reports the paper form will be used to submit to GSK as per the', 'table in Section 12.4.1 above\". Added', '98']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.9.3.', 'Protocol Amendment 3', 'Protocol changes for Amendment 03, from protocol changes to amendment 02 (21-', 'Feb-2014)', 'Scope: This amendment applies to all sites', 'Amendment 03 Summary and Rationale', 'Strike through text refers to deleted text and underlined refers to added text.', 'List of Specific Changes', 'Section 1 Objective(s)/Endpoint(s) and Section 3 Objective(s)/Endpoint(s)', 'Rationale for change: Rate of COPD exacerbations endpoints from tertiary to', 'exploratory due to stopping criteria.', 'Revised text:', 'Exploratory', 'To explore the effect of UMEC/VI', 'Rate of mild, moderate or severe', '(62.5/25 mcg once daily), UMEC', 'exacerbations', '(62.5 mcg once daily) with salmeterol', '(50 mcg twice daily) on rate of COPD', 'Rate of moderate or severe', 'exacerbation', 'exacerbation', 'Section 1. Overall Design', 'Rationale for change: To clarify study design and content of section to agree with', 'Section 4.1', 'Revised text:', 'There will be a total of 5 clinic visits and one follow-up phone call (Visit 6). A pre-', 'screening visit (Visit 0) may be required in order to administer the informed consent', \"before any changes are made to the subject's current medication regimen. If no changes\", 'in medication are required, V0 (pre-screening) and V1 (screening) may be conducted on', 'the same day. Inhaled long-acting muscarinic antagonist (LAMA) or long-acting beta2-', 'agonist (LABA) and/or albuterol/salbutamol as needed (rescue medication) are not', 'exclusionary prior to Screening or during the run-in.', 'Eligible subjects at Screening Visit 1 will be current or former smokers, at least 6 weeks', 'ICS and ICS/LABA free with an FEV1 post-albuterol/salbutamol of \"30% to <80%', 'predicted normal and a FEV1/FVC <0.7 and a CAT score >10.', 'Subjects using inhaled LAMA or LABA medication must withhold their morning dose', 'prior to Screening spirometry. Subjects who meet all other eligibility criteria at Screening', 'will enter a run-in period for 4 weeks. During the run-in period, subjects will continue', 'with their inhaled LAMA or LABA. In addition, subjects will be provided with short', 'acting albuterol/salbutamo) as needed for relief of COPD symptoms (rescue medication)', '99']\n\n###\n\n", "completion": "END"}